期刊
MOLECULAR PSYCHIATRY
卷 9, 期 7, 页码 705-710出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.mp.4001473
关键词
Alzheimer's disease (AD); mild cognitive impairment (MCI); conversion; prognosis; cerebro-spinal fluid (CSF); tau; beta-amyloid; prediction; biomarker; early diagnosis
Subjects with mild cognitive impairment (MCI) are at a high risk of developing clinical Alzheimer's disease ( AD). We asked to what extent the core biomarker candidates cerebro-spinal fluid (CSF) beta-amyloid(1-42) (Abeta(1-42)) and CSF tau protein concentrations predict conversion from MCI to AD. We studied 52 patients with MCI, 93 AD patients, and 10 healthy controls (HC). The MCI group was composed of 29 patients who had converted to AD during follow-up, and of 23 patients who showed no cognitive decline. CSF A(beta1-42) and tau protein levels were assessed at baseline in all subjects, using enzyme-linked immunosorbent assays. For assessment of sensitivity and specificity, we used independently established reference values for CSF A(beta1-42) and CSF tau. The levels of CSF tau were increased, whereas levels of A(beta1-42) were decreased in MCI subjects. A(beta1-42) predicted AD in converted MCI with a sensitivity of 59% and a specificity of 100% compared to HC. Tau yielded a greater sensitivity of 83% and a specificity of 90%. In a multiple Cox regression analysis within the MCI group, low baseline levels of A(beta1-42), but not other predictor variables (tau protein, gender, age, apolipoprotein E epsilon4 carrier status, Mini Mental Status Examination score, observation time, antidementia therapy), correlated with conversion status (P<0.05). Our findings support the notion that CSF tau and A(beta 1-42) may be useful biomarkers in the early identification of AD in MCI subjects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据